AKT-DC (Activated Killer T-cells and dendritic cells)
Until 2012, Dr Hideki Kimura and his team conducted AKT-DC therapy in Chiba Cancer Center as part of government’s clinical study for advanced medical treatment.
It induces CTL’s (Cytotoxic T lymphocytes) activation by culturing autologous draining lymph nodes from cancer tissue which is obtained during surgery.
DC (Dendritic cells) representing multiple cancer antigens of patients naturally exist in the lymph nodes of cancer patients. Hence, Killer T cells will be proliferated by these antigen presentation without any stimulation of anti-CD3 antibody. As a result, more of the proliferated lymphocytes are activated as CTLs.
Therefore, It can be said that this is an ideal tailor made type of individualized immune cell therapy for cancer recurrence prevention of post-surgery patients.
Kimura, H (Chibaken Saiseikai Narashino Hospital). et al (2014) Randomized controlled phase III trial of adjuvant chemo-immunotherapy with activated killer T cells and dendritic cells in patients with resected primary lung cancer, Cancer Immunology Immunotherapy, DOI 10.1007/s00262-014-1613-0.
Between April 2007 and July 2012, 103 postsurgical non-small cell lung cancer patients were randomly assigned to receive either chemo-immunotherapy (group A) or chemotherapy only (group B). The immunotherapy consisted of the adoptive transfer of autologous activated killer T cells and dendritic cells obtained from lung cancer patients’ regional lymph nodes.
Figure 1. shows overall survival rate; 5-year survival rate for group A was 81.4% and group B was 48.3%. The difference was statistically significant (log-rank test p=0.0005, generalized Wilcoxon test p=0.0005) between group A and B and thus validates the effects of immune cell therapy. Based on hazard ratio, group A presented 4.36 times higher probability of 5-year survival rates.
Figure 2. shows 2 and 5-year recurrence-free survival rates, which was 56.8 % (40.3–70.3) in group A and 26.2 % (13.1–41.5) in group B, respectively. The difference was statistically significant (log-rank test p=0.0020), validating effects of immune cell therapy. Hazard ratio for group A was 1/0.423 meaning their 5-year survival rate was 2.36 times higher.
The graphs shown in figure 1 and 2 represents the effectives of AKT-DC therapy against recurrence of lung cancer. The research which was also published in international science journals, was based on randomized controlled phase III trial for adjuvant chemo-immunotherapy. This research showed that 5-year recurrence/overall survival rate was increased by 30% with AKT-DC therapy. Even in case of cancer recurrence, the intervals of recurrence was significantly delayed.
We offer this ground-breaking treatment to not only lung cancer but to other tumorous cancer patients in cooperation with their oncologists.
What HR=0.229(HazardRatio) means:
If the survival rate of untreated (i.e. untreated from immune cell therapy) patients is 1, the survival rate of treated (immune cell therapy) patient is 1/0.229=4.36 times higher.
For example, the untreated patients group’s 5-year survival rate was 10% whereas the treated patients’ 5-year survival rate was 43.6%. Recurrence-free rate also went up by 2.36 times (1/0.423).